Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Bone Marrow Transplantation|April 14, 2015
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantationMarina Konopleva, Christopher B Benton, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2013
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myelomaQaiser Bashir, Hassan Khan, Peter F Thall, et al.
Transplantation and Cellular Therapy|May 26, 2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study OutcomesGheath Alatrash, Chantal Saberian, Roland Bassett, et al.
Cancer Treatment and Research Communications|January 20, 2022
Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung CancerSteven H Lin, Heather Y Lin, Vivek Verma, et al.
Bone Marrow Transplantation|May 24, 2022
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantationBorje S Andersson, Peter F Thall, Junsheng Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumorsFadlo R Khuri, Bonnie S Glisson, Edward S Kim, et al.
Science Translational Medicine|April 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapyPavlos Msaouel, Sangeeta Goswami, Peter F Thall, et al.
Urologic Oncology|November 5, 2024
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meetingStephanie A Berg, Salvatore La Rosa, Tian Zhang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 5, 2026
Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T CellsAmanda Olson, Ye Li, David Marin, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
Pageof 20